An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.
about
Neurotoxins: free radical mechanisms and melatonin protectionMelatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug.Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?Distribution of melatonin MT1 receptor immunoreactivity in human retinaMelatonin in Alzheimer's disease and other neurodegenerative disordersSevere Cognitive Dysfunction and Occupational Extremely Low Frequency Magnetic Field Exposure among Elderly Mexican AmericansCellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disordersMelatonin metabolism in the central nervous system.The antiapoptotic activity of melatonin in neurodegenerative diseases.Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer diseaseAntiinflammatory activity of melatonin in central nervous systemMelatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging.Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease.Antioxidants as treatment for neurodegenerative disorders.Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease.Melatonin improves the quality of in vitro produced (IVP) bovine embryos: implications for blastocyst development, cryotolerance, and modifications of relevant gene expressionThe interaction between amyloid-β peptides and anionic lipid membranes containing cholesterol and melatoninMelatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems.Protective effects of walnut extract against amyloid beta peptide-induced cell death and oxidative stress in PC12 cells.Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregationThe human pineal gland and melatonin in aging and Alzheimer's disease.Melatonin Therapy in Patients with Alzheimer's Disease.Therapeutic application of melatonin in mild cognitive impairment.Melatonin in Alzheimer's diseaseMelatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.Aging, circadian rhythms and depressive disorders: a review.Melatonin and cancer: current knowledge and its application to oral cavity tumours.The role of mitochondria in brain aging and the effects of melatonin.Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review.Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.Mechanisms of Melatonin in Alleviating Alzheimer's Disease.Melatonin prevents nitric oxide-induced apoptosis by increasing the interaction between 14-3-3beta and p-Bad in SK-N-MC cells.Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH acting as a highly potent antioxidant agent.Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.Clinical aspects of melatonin intervention in Alzheimer's disease progressionNose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats.
P2860
Q22305781-6A2AF55D-3B59-4C43-91E0-F73B11137C5DQ24815611-0E6209E9-E757-4878-8D05-60D21D00AA2DQ28070156-8D7498E4-6EB8-4A16-99E2-CC6836AC21FDQ28207725-66415303-4193-4C32-BF14-C5D9F0350F8CQ28217483-C9740103-0723-43BA-9A66-102864BC9FE3Q28385828-2526D74C-4059-4FB4-BECC-3AB4E3D8342BQ28754228-04438838-84CC-4FF9-8E27-CDDDB4205F68Q30476606-090443F6-A718-4915-BD94-8DB682DA38EEQ33757816-B86A3009-F02E-40CF-99BE-072FCEA89B4EQ34402167-40616502-E4D3-473D-8157-ACF8A4534445Q34402174-7AA6E2EC-0E79-4D91-905F-703B58BCA913Q34416921-5AC0C11D-0CA2-40A2-B048-EB826783956BQ34614504-963638AF-A89F-4564-B363-A6C5AE5B1F9BQ34721350-87E15A76-BE93-4710-AB9E-6C203952814EQ34974866-B088403D-241E-4ECF-9B96-07480260E306Q34993154-8F822B76-F8C3-4E2A-A0A1-BCD785FB1762Q35138531-D5AD11F2-352B-495D-85F2-451E6C2FC702Q35184913-235A0C30-8E5B-4F86-A06B-9A8C737EFAB4Q35204424-2DF9372B-40E0-46BA-A232-E7F44B4CC7D4Q35242946-102A4739-9609-4E7B-AB42-B63D8178731AQ35366778-6C74514D-39B1-4E8E-86A0-437AE04D7ED9Q35607228-D9046A3D-FC71-4618-AD64-B5F736F93D35Q36051556-ED59D835-526B-4383-85F4-8C677332C5FDQ36335048-59A39D37-A723-4D55-A38B-1B29E45CB54EQ36576496-ED6F35BC-DBE9-4836-A244-CE5212B3D234Q37091982-C6A2A44C-73D3-4FDA-8EEA-A37C3AD2F5A5Q37097780-E8E68DE8-9EC2-407B-9392-F5EC033A1B78Q37253704-43359B6C-01F7-4E11-9FEB-1AACCB176970Q37366995-26DE8993-B341-4D42-A643-7B515AC7DD85Q37834066-6FEB4CE3-8112-4472-B2E0-F48FB9BC270CQ37848076-A3D4D3C8-83BB-4CA6-940F-D49088F5E977Q38022179-68261C09-0044-4763-9EB8-5C886A33D00DQ38191261-3E6AC201-5C14-4C86-8B40-B13F0ADB5604Q38243554-8DFC37CA-ADF5-48D3-93B7-7071A23F8173Q39178920-F46C9422-6F1E-472A-AA17-DD86055B9B98Q40035877-F7457737-D4FB-4A23-AE8D-2F4CBF57CD80Q40379290-0B12806C-3270-4188-ADE3-193F29F77BBBQ40477472-D029A49D-C185-454E-B86B-2C7C268DA696Q41136734-3A7C8922-8651-4C15-BF64-927FB5727C0BQ42011994-D25CA516-3C5D-47E5-BEA7-4484B387F7CF
P2860
An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
An assessment of the antioxida ...... tions for Alzheimer's disease.
@ast
An assessment of the antioxida ...... tions for Alzheimer's disease.
@en
type
label
An assessment of the antioxida ...... tions for Alzheimer's disease.
@ast
An assessment of the antioxida ...... tions for Alzheimer's disease.
@en
prefLabel
An assessment of the antioxida ...... tions for Alzheimer's disease.
@ast
An assessment of the antioxida ...... tions for Alzheimer's disease.
@en
P2093
P356
P1476
An assessment of the antioxida ...... tions for Alzheimer's disease.
@en
P2093
B Frangione
B Poeggeler
M A Pappolla
R J Reiter
P2888
P304
P356
10.1007/S007020050018
P577
2000-01-01T00:00:00Z